A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

Osteoporosis, Postmenopausal Clinical Trial

Official title:

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01250145
• Other study ID #: 13764
• Secondary ID: I2Y-EW-GHFO
• Status: Completed
• Phase: Phase 1
• First received: November 29, 2010
• Last updated: September 21, 2012
• Start date: November 2010
• Est. completion date: May 2011

Study information

• Verified date: September 2012
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 1, multi-center, 2-part, subject- and investigator-blind, randomized, placebo-controlled, multiple dose study of transdermal teriparatide (80-µg dose) in healthy postmenopausal women. Part A will examine the cumulative irritation and adherence of the transdermal patch, and Part B will examine skin sensitization and adherence. Two separate groups of subjects will be enrolled for Part A and Part B of the study. All screening procedures will take place up to 28 days prior to enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 251
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Are overtly healthy postmenopausal females, as determined by medical history, physical examination, vital signs, electrocardiogram (ECG), and laboratory tests (for example, subjects who have osteoporosis or stable and/or controlled hyperlipidemia, hypertension, and/or hypothyroidism may be entered if that investigator judges it appropriate for participation in this study).

• Postmenopausal women include women with at least 6-weeks postsurgical bilateral oophorectomy with or without hysterectomy, confirmed by medical history, or spontaneous amenorrhea for at least 6 to 12 months, not induced by a medical condition such as anorexia nervosa and not taking medications during the amenorrhea that induced the amenorrhea (eg, oral contraceptives, hormones, gonadotropin-releasing hormone, anti-estrogens, selective estrogen receptor modulators, or chemotherapy) and a follicle-stimulating hormone level greater than 40 mIU/mL.

• Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.

• Have a sitting blood pressure and pulse rate that are judged to be not clinically significant by the investigator.

• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

• Have given written informed consent approved by Eli Lilly and Company (Lilly) and the ethical review board (ERB) governing the site.

Exclusion Criteria:

• Are currently enrolled in, or discontinued within the last 3 months from, a clinical trial involving an investigational drug or device or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

• Have known hypersensitivity to teriparatide or to any of its excipients.

• Are persons who have previously completed or withdrawn from this study or any other study investigating teriparatide patch.

• Have an abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.

• Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data.

• Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.

• Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.

• Show evidence of hepatitis C and/or positive hepatitis C antibody.

• Show evidence of hepatitis B and/or positive hepatitis B surface antigen.

• Have a history of breast cancer within the past 10 years or other types of carcinoma within the past 5 years, except for excised superficial skin tumors and adequately treated in situ carcinoma of cervix.

• Have an average weekly alcohol intake that exceeds 14 units per week,

(1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).

• Have hyperparathyroidism or hypoparathyroidism.

• Have hyperthyroidism.

• Have hypercalciuria (24-hour collection above 300 mg/day).

• Have hypercalcemia (above the upper limit of reference range).

• Have a history of bone diseases such as Paget's disease of bone, bone carcinoma, bone metastases, metabolic bone disease other than osteoporosis, or unexplained elevation in serum alkaline phosphatase level.

• Have a history of external beam or implant radiation involving the skeleton.

• Have a history of recurrent nephrolithiasis, or a single episode within the past 5 years. Eligible subjects who have had an episode within the past 5 to 10 years must have a kidney-ureter-bladder X-ray of the abdominal area within 1 month prior to enrollment in the study, which indicates no existing stone.

• Have a history of bleeding disorder within the past 3 years.

• Are currently using therapies for osteoporosis; or using hormone replacement therapy or bisphosphonates during the previous 3 months. Women receiving short-term hormone therapy for the treatment of moderate to severe menopausal symptoms may be enrolled if their postmenopausal status is confirmed by inclusion criterion.

• Have presence of a dermatologic disease that might interfere with the evaluation of the test site reaction; and clinically significant scars, wounds, or discoloration, or abnormalities of the skin at or near the intended site of electrode application (for example, porphyria, atopy, psoriasis, vitiligo).

• Have a history of severe skin infection within the past year in the opinion of the investigator.

• Have a history of skin allergy or hypersensitivity to tapes or adhesives, in the opinion of the investigator.

• Have a history of significant dermatologic cancers (for example, melanoma, squamous cell carcinoma), except basal-cell carcinomas that were superficial and did not involve the investigative site.

• Have an obvious difference in skin color between arms or the presence of a skin condition, excessive hair at the application sites, scar tissue, tattoo, or coloration that would interfere with placement of test articles, skin assessment, or reactions to drug.

• Have implanted or externally mounted electrical or electronic medical devices (for example, pacemakers).

• Have used topical analgesics or topical corticosteroids within 3 weeks of study enrollment.

• Have taken antihistamines within 72 hours prior to dosing.

• Any other condition which, in the opinion of the investigator, would preclude participation in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Osteoporosis, Postmenopausal

Intervention

Drug:
• LY333334
Transdermal patch
• Placebo
Transdermal patch

Locations

Country	Name	City	State
Germany	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	München
Germany	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Schenefeld
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Plymouth	Devon
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Daytona Beach	Florida
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Honolulu	Hawaii

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A - Cumulative Skin Irritation by Draize Score	Number of evaluation points (patches) showing defined Draize score. Erythema and edema were used to determine skin irritation. Score 0 = No Erythema/Edema; Score 1 = Very slight Erythema/Edema (barely perceptible); Score 2 = Well defined Erythema/Edema (edges of area well defined by definite raising); Score 3 = Moderate to Severe Erythema/Edema (raised approximately 1 millimeter [mm]).	Day 1 through Day 22	Yes
Primary	Part B - Skin Irritation and Sensitization by Draize Score	Number of evaluation points (patches) showing defined Draize score. Erythema and edema were used to determine skin irritation and sensitization. Score 0 = No Erythema/Edema; Score 1 = Very slight Erythema/Edema (barely perceptible); Score 2 = Well defined Erythema/Edema (edges of area well defined by definite raising); Score 3 = Moderate to Severe Erythema/Edema (raised approximately 1 mm); Score 4 = Severe Edema (raised more than 1 mm and extending beyond area of exposure).	Days 1 - 19 and 34 - 37	Yes
Secondary	Part A - Patch Adhesion Score	Number of patches with adhesion score. Score 0 = =90% adhered (essentially no lift off the skin); Score 1= =75% to <90% adhered (some edges only lifting off the skin); Score 2 = =50% to <75% adhered (less than half of the patch lifting off the skin); Score 3 = >0% to <50% adhered but not detached (more than half of the patch lifting off the skin without falling off); Score 4 = 0% adhered - patch detached (patch completely off the skin).	Day 1 through Day 22	No
Secondary	Part B - Patch Adhesion Score	Number of patches with adhesion score. Score 0 = =90% adhered (essentially no lift off the skin); Score 1= =75% to <90% adhered (some edges only lifting off the skin); Score 2 = =50% to <75% adhered (less than half of the patch lifting off the skin); Score 3 = >0% to <50% adhered but not detached (more than half of the patch lifting off the skin without falling off); Score 4 = 0% adhered - patch detached (patch completely off the skin).	Days 1 - 19 and 34 - 37	No